Clinical trials: Healthy Participant Study
Non-alcoholic Steatohepatitis
Safety, Tolerability, and Pharmacokinetics of ACT500 in Healthy Adult Participants
This is a single-center, randomized, double-blind, placebo-controlled Phase I clinical study, divided into two parts. The first part is a single-dose escalation study (Part1,SAD study phase), and the second part is a…
- Trial name
- NCT06716905
- Testing
- ACT500 tablets
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Esophageal Motility Disorders
Codeine on Pharyngeal and Esophageal Motility
Opioids act on opioid receptors located in the brain as well as in the gastrointestinal (GI) tract to induce changes in motility.
- Trial name
- NCT03784105
- Testing
- Codeine Phosphate, Siripus simplex
- Where
- 2 sites in Belgium
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Malaria, Vivax
A Study to Assess the Effects of Dissolution Profile on the Pharmacokinetics of Single Oral Doses of Tafenoquine Tablets and Tafenoquine Stable Isotope Labelled Solution
This study will investigate the effect of Tafenoquine (TQ) 150 mg tablet ageing (dissolution profiles) on human exposure of TQ comparing the relative bioavailability of TQ from tablets exhibiting different dissolution profiles in…
- Trial name
- NCT02751294
- Testing
- Tafenoquine Control, Tafenoquine dissolution profile X, Tafenoquine SIL
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteers
A Study to Evaluate the Bioavailability of Risankizumab Following Subcutaneous Dosing in Healthy Male Participants
The objective of this study is to evaluate the bioavailability, safety and tolerability of risankizumab following subcutaneous injections in healthy male participants.
- Trial name
- NCT05283694
- Testing
- risankizumab
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AbbVie
Acne Vulgaris
A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers
The purpose of this study is to evaluate the potential of Tazarotene Foam to induce a phototoxic reaction when exposed to UV and VIS light on skin of healthy volunteers.
- Trial name
- NCT01115322
- Testing
- Tazarotene Foam without irradiation, Tazarotene Foam with UVA and UVB irradiation, Tazarotene Foam with UVA, UVB, and visible light
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Stiefel, a GSK Company
Healthy
An Investigation Of The Absorption And Pharmacokinetics Of A Single Dose Of A Controlled Release (CR) Pregabalin Tablet Following A Low, Medium, And High-Fat Evening Meal As Compared To A Single Dose Of The Immediate Release (IR) Pregabalin Capsule In Healthy Volunteers
The purpose of this study is to 1) evaluate the extent of absorption of a single dose of a pregabalin controlled release tablet following either a low, medium, or high-fat evening meal as compared to a single dose of the…
- Trial name
- NCT01257529
- Testing
- Pregabalin controlled release, 330 mg, low-fat, Pregabalin controlled release, 330 mg, medium-fat, Pregabalin controlled release, 330 mg, high-fat
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia
Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers
This is an open label study in 4 cohort of 4 healthy volunteers each designed to evaluate the dopamine receptor occupancy of LB-102 at various doses and timepoints.
- Trial name
- NCT04588129
- Testing
- LB-102
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- LB Pharmaceuticals Inc.
Prevention of Infection With HIV-1
Safety Study of Ibalizumab Subcutaneous Injection in Healthy Volunteers
The is a blinded safety study of ibalizumab given by subcutaneous injection in sequentially increasing dose-groups of at-risk, HIV-negative, healthy volunteers.
- Trial name
- TMB-108 (NCT01292174)
- Where
- 6 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- TaiMed Biologics Inc.
Tuberculosis
Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers
This is a Phase I, single-center, double-blinded, randomized, placebo-controlled, five-period cross-over clinical study of PA-824 to evaluate the effect of PA-824 and of PA-824 plus moxifloxacin on cardiac repolarization (QT/QTc…
- Trial name
- NCT01674218
- Testing
- Moxifloxacin, PA-824
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy Volunteers, fMRI Research
Frequency Effects of Transcutaneous Trigeminal Nerve Stimulation (eTNS) on Brain and Autonomic Function
This study aims to investigate how different frequencies of transcutaneous Trigeminal Nerve Stimulation (eTNS) affect brain activity and the autonomic nervous system in healthy individuals.
- Trial name
- NCT07662291
- Testing
- 2Hz Transcutaneous Trigeminal Nerve Stimulation, 120Hz Transcutaneous Trigeminal Nerve Stimulation
- Where
- China
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Xidian University
Cancer, Vomiting
An Open-label, Single Dose Pharmacokinetic Study of 14 mg Granisetron Patch in Healthy Subjects
The objective of the study is to characterize the pharmacokinetic profile of granisetron patch after single administration to healthy subjects.
- Trial name
- Granisetron (NCT00954291)
- Where
- Taiwan
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Taipei Medical University WanFang Hospital
Healthy
A Study to Evaluate Safety, Acceptability, Pharmacokinetics, and ex Vivo Pharmacodynamics of TMC278 Long Acting Formulation in HIV-1 Seronegative Participants
The purpose of this study is to evaluate the safety, acceptability, pharmacokinetics (what the body does to the medication), and ex vivo (tested outside the body) pharmacodynamics (what the medication does to the body) of TMC278…
- Trial name
- NCT01656018
- Testing
- TMC278, Long acting (LA)
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy Volunteers and Asthma
A Study of CNTO 3157 in Healthy Normal and Asthmatic Participants Inoculated With Human Rhinovirus Type 16
The main purposes of this study are to evaluate the safety (Parts 1 and 2) and efficacy (Part 2) of pretreatment with CNTO 3157 in healthy adult and asthmatic adult participants before and after intranasal (into the nose)…
- Trial name
- NCT01704040
- Testing
- CNTO 3157 (healthy participants), CNTO 3157 (asthmatic patients), HRV-16
- Where
- 13 sites in Belgium, Canada and 4 more
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Hepatic Impairment
Pharmacokinetics of Dabrafenib in Subjects With Hepatic Impairment
To characterize the pharmacokinetics and safety of dabrafenib following a single 100 mg oral dose in subjects with moderate and severe hepatic impairment.
- Trial name
- NCT02873650
- Testing
- dabrafenib
- Where
- 4 sites in United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Healthy
Study Analyzing the Effect of Rifampicin Administration on the Pharmacokinetics of Neramexane Mesylate
Primary Objectives: Assess the effects of poly-specific cytochrome P450 and drug-transporter induction by repeated dose Rifampicin (600 mg/day) co-administration on the single-dose pharmacokinetics of Neramexane.
- Trial name
- NCT00955760
- Testing
- Neramexane
- Where
- Germany
- Volunteers
- healthy volunteers welcome
- Sponsor
- Merz Pharmaceuticals GmbH
Chronic Obstructive Pulmonary Disease
Second Follow-up Study of COPD Patients and Healthy Controls for Evaluation of Predictive Non-coding RNA Biomarkers
Between 2012 and 2014, a cohort of 90 COPD subjects of disease severity grades GOLD I-IV as well as 60 healthy control subjects (30 smokers and 30 non-smokers) have been examined regarding different clinical and blood/ sputum…
- Trial name
- Ribo III (NCT04895124)
- Where
- Germany
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Fraunhofer-Institute of Toxicology and Experimental Medicine
No Condition, Brain GABA-B Function
GABA-B Receptor Function in Healthy Volunteers
There are several developing lines of evidence suggesting that brain receptors called GABA-B receptors play a significant role in addiction and its treatment.
- Trial name
- NCT01563224
- Testing
- Baclofen 10mg, Baclofen 60mg
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Healthy Volunteers
SAD and MAD Study of FTX-101 in Healthy Male Subjects
This is a Phase 1, first-in-human (FIH), single-center, randomized, double-blind, placebo-controlled study in healthy male subjects.
- Trial name
- NCT06617546
- Testing
- FTX-101
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Find Therapeutics
Healthy Volunteers
Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSV∆G-ZEBOV-GP Vaccine)
Background: The Ebola virus causes a severe disease that can be fatal. The usual incubation period to illness after being exposed is 2 to 21 days. There are only limited treatments currently available for Ebola infection.
- Trial name
- NCT02788227
- Testing
- rVSV∆G-ZEBOV-GP Vaccine (V920)
- Where
- 3 sites in United States, Canada
- Volunteers
- 248 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)
Healthy
Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects
The purpose of the study is to evaluate the safety, tolerability, PK and PD of a single-dose of ALXN1007 in healthy volunteers.
- Trial name
- NCT01454986
- Testing
- ALXN1007
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Alexion Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.